{"name":"Recognify Life Sciences","slug":"recognify-life-sciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQejlyd2VteDg4WlZSdWppMVc5dXU5MHZJejJWNmh2YW5NRVY4NHFoR19NOFlTNE94OF9rb2YzWEZjeTFRODFGdE8zRUEzUi1BOGF3NndTTEUyZ0hFYTBIbmJ3UjBQNEk5VFpSNEMyZkltRjBqcTkzSkpXZHVYejdTeEJNZVdOS0QwMEJjNUhrZlFWYncyeHdHQVZKcw?oc=5","date":"2026-03-26","type":"pipeline","source":"openPR.com","summary":"Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com","headline":"Cognitive Impairment Associated with Schizophrenia Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9YWVJaSFJITUpkbHB2b1F2MjNRSVpzTElRWTVmRjJFYll3X3lXYWJRUG9rcEptNmF5OTFnQ2NWUHNiNnFBcWZYdVZGdTJqTkNweGZQWHVQQXN6dU4wRGxhNHlNbFBBeEJDOXRpaw?oc=5","date":"2025-12-03","type":"pipeline","source":"MedPage Today","summary":"Ozempic Improves Glycemic Control, Cuts Weight in Schizophrenia Patients - MedPage Today","headline":"Ozempic Improves Glycemic Control, Cuts Weight in Schizophrenia Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPdTU4WFFQdXlReGVnLVBCSjl2TEdaS21yWmtWVTl1VVVyUktSZFFmbmpNQTNtendiOEJDQnZ3UUk1ZmtvazltOHpOUzRJeTF4QS1YcHhud21VVFVtRG1XYk5pMlMyVmgxNDJneldRSkxwZmhDd0Z1RDEzQjFyRWx6N2wzOHpab2lGTU4tN2ZJeEk2RmpWaE1zMFpDTkxkcUVKb3c?oc=5","date":"2025-07-28","type":"trial","source":"BioPharma Dive","summary":"Atai backs away from schizophrenia drug after trial failure - BioPharma Dive","headline":"Atai backs away from schizophrenia drug after trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQSWNXclNiYjl1RG5UcEo3RHBMZExwcngwTGoyTnYwaWN2Nl8ySm9CZTlsZ0JrYm5SSk5PcHdVeHV0QVNELUhjaGdXTlcxSGhZeUJyeXlNMlEwUUZ2bUZMZ2NQMmhYb2w4cl9laGFWRmlTdTNfY256b3FLanRjdExLOUhQRjJuQ19vbkJTWWI4Tk5pUUl0YUpVY2d0RW5nam8?oc=5","date":"2025-07-28","type":"trial","source":"BioSpace","summary":"Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial - BioSpace","headline":"Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5OZ21FaUNqMTE2RDhzeUJXSDIxZ2JqUWJKMjhjOGZmZndZUVdocXNhOHg2dWxIS2s4QjdCRGszRFFvbzdWT1lEMHRRLS0tNWtNdTJQTkZmR2dTZjcyZFB3R21USGNRLVFPR0RXeWJlaUpHdDFXUGh0ajF1QThRQQ?oc=5","date":"2025-07-28","type":"trial","source":"Clinical Trials Arena","summary":"Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal - Clinical Trials Arena","headline":"Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQb2pWR3JSeVFsNWZqeGQ0Yl9IMlpLWi1OVVlFWUYzRnQ3Ti1FLWN1TEhXQm9sZ0N1azFCTzVJVE84em4xbFlGVXpLSVowSnNPMGRuVnhUYzVkV1dmZDRYeXpZWjdJOGUzRW1ZM0hobDBnYlNXMVY5a1F5eUloTlM4aldaNm80YTkyNU9mTWNUazlVTmppM1J2VHY4UUI5Sk9wRlE?oc=5","date":"2025-07-28","type":"trial","source":"Fierce Biotech","summary":"Atai's schizophrenia drug fails to improve cognition in phase 2 study - Fierce Biotech","headline":"Atai's schizophrenia drug fails to improve cognition in phase 2 study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOQkFuQW1neXlOQ01pNU9CX0dlS3RveTB4S2EwZlFNMGRUczkyMERxWVQzd2cwR1c5U280UXM0UHFrR0lfZHlhOVVfaUw5ZjZyZUtTSm5LOVBCUi1PLUtuZnV3a3BYekRoMFluYW1IMTZXY01zRURLZDJ1QzRaT2Y3X2dnRmx2cmIyRV9MWW5SOXluM2JMcWk3RFdZMkxjQ2k5TEV5RE1jSVAzMUJaWUdlZTNEaEs?oc=5","date":"2025-07-25","type":"pipeline","source":"Seeking Alpha","summary":"Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha","headline":"Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOUUlrVW9ReFdVam51b0tGVFRzNHk4akpfMUpINEIyQ0pQUl93TFZYNjJ3Rlg0V25MbVNRd3l0emI2NWZ2S2hvV2FhelRxbURmYjlyVlVtbXR4UE5Xd3hQQlpxck5BekhFU1hBdnc0alBjbldKa2ZqdzhNZmJlUnNwVkNUWGZuaHpGYldVS0g5RV9MSkM4SFRDRlgwaw?oc=5","date":"2024-09-13","type":"pipeline","source":"Fierce Biotech","summary":"Neurocrine's bid to save schizophrenia prospect fails - Fierce Biotech","headline":"Neurocrine's bid to save schizophrenia prospect fails","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQa2o2MEhIdWZIWnlaVGFVSTV3ZWZ2NUZvVmFsTUd3ZW9vblNlbVVYNEJDRUYtM0NWMk45T1hqUHd4Q1RYd19aaVA2dnUwREdDSmlwS0ozcEVpMm9wZVUzdFZnd2xQWlJsMjFZMkRyV3N2M0h2bDV2TnFpZmpyVkFlSGthcF9aT2JSVk51YUJMNWcwMVV5dEkxT2NQaHhNeHFBUDVIeTk4TE1idHdzU3BOZU1pbldiLUZUVmhyZHNyOEhzZi1ZV1g5ZHh6ek1LMGtlRk5UWEwwQW9VOGtCQ0xRLUhrRENjYzFVUWZheFNUOXQxQXhaeWxZeFA4a3BUQ3kwaUhB?oc=5","date":"2023-04-05","type":"trial","source":"PR Newswire","summary":"Schizophrenia Clinical Trials Pipeline Analysis: 60+ Companies are Working to Improve the Treatment Space | DelveInsight - PR Newswire","headline":"Schizophrenia Clinical Trials Pipeline Analysis: 60+ Companies are Working to Improve the Treatment Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5GMnZoeTgyWGtzZ3BfWG5lV2xGbnhtc3BmaGVQZEVmQW5VZ3RNUTZuSVhOM0FlYl9feXphWXFsZ2tvRUFyWlNZc256TzFsVzhfNjNkUlFzM0QtZHZ3Tjh1dmFIVEFNXzhrMl9USlhmeUlTS2daR1gxaFFMbw?oc=5","date":"2021-04-23","type":"pipeline","source":"Nanalyze","summary":"ATAI Life Sciences Stock – A Psychedelic IP Powerhouse - Nanalyze","headline":"ATAI Life Sciences Stock – A Psychedelic IP Powerhouse","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}